Literature DB >> 28278723

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.

Abhishek Maiti1,2, Jorge Cortes2, Alessandra Ferrajoli2, Zeev Estrov2, Gautam Borthakur2, Guillermo Garcia-Manero2, Elias Jabbour2, Farhad Ravandi2, Susan O'Brien3, Hagop Kantarjian2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28278723      PMCID： PMC5478443          DOI： 10.1080/10428194.2017.1283030

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

Review 1.  How I treat newly diagnosed chronic phase CML.

Authors:  Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

Review 2.  Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Authors:  Yasmin Rosshandler; Ann Q Shen; Jorge Cortes; Hanna Jean Khoury
Journal:  Expert Rev Hematol       Date:  2016-04-21       Impact factor: 2.929

3.  Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.

Authors:  A J Tipping; F X Mahon; G Zafirides; V Lagarde; J M Goldman; J V Melo
Journal:  Leukemia       Date:  2002-12       Impact factor: 11.528

4.  A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.

Authors:  Rong Chen; Varsha Gandhi; William Plunkett
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

5.  How I treat CML blast crisis.

Authors:  Rüdiger Hehlmann
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

6.  Integrating current treatment options for TKI-resistant chronic myeloid leukemia.

Authors:  Jerald P Radich; Neil P Shah; Michael J Mauro
Journal:  Clin Adv Hematol Oncol       Date:  2014-07

7.  In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.

Authors:  Barbara Scappini; Francesco Onida; Hagop M Kantarjian; Li Dong; Srdan Verstovsek; Michael J Keating; Miloslav Beran
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

Review 8.  Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

9.  Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.

Authors:  P D le Coutre; F J Giles; A Hochhaus; J F Apperley; G J Ossenkoppele; R Blakesley; Y Shou; N J Gallagher; M Baccarani; J Cortes; H M Kantarjian
Journal:  Leukemia       Date:  2011-11-11       Impact factor: 11.528

10.  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

Authors:  Koji Sasaki; Sara S Strom; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Naveen Pemmaraju; Naval Daver; Preetesh Jain; Sherry Pierce; Hagop Kantarjian; Jorge E Cortes
Journal:  Lancet Haematol       Date:  2015-04-20       Impact factor: 18.959
View more
  3 in total

1.  Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.

Authors:  Jian Chen; Qitian Mu; Xia Li; Xiufeng Yin; Mengxia Yu; Jing Jin; Chenying Li; Yile Zhou; Jiani Zhou; Shanshan Suo; Demin Lu; Jie Jin
Journal:  Oncotarget       Date:  2017-06-20

Review 2.  New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.

Authors:  Peter E Westerweel; Peter A W Te Boekhorst; Mark-David Levin; Jan J Cornelissen
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

3.  Anti-leukemic and anti-angiogenic effects of d-Limonene on K562-implanted C57BL/6 mice and the chick chorioallantoic membrane model.

Authors:  Bhavini B Shah; Ruma Baksi; Kiranj K Chaudagar; Manish Nivsarkar; Anita A Mehta
Journal:  Animal Model Exp Med       Date:  2018-11-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.